Ignite Creation Date:
2025-12-24 @ 3:20 PM
Ignite Modification Date:
2026-01-02 @ 2:19 PM
Study NCT ID:
NCT03787992
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-04-11
First Post:
2018-12-18
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）
Sponsor:
Allist Pharmaceuticals, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
201801215
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None